A technician at Regeneron Pharmaceuticals’ headquarters in Tarrytown, New York.
Mike Segar | Reuters
Regeneron and Roche are working together to develop a cocktail of antibody investigations against Covid-19, with the U.S. company selling it in the United States and the Swiss drugmaker selling it elsewhere should the drug win approval.
Regeneron has said it expects first data next month from ongoing trials of its Covid-19 antibody cocktail, named REGN-COV2.
The drugs, including several being developed by drugmakers seeking treatment for the new coronavirus, prevented and treated the disease in rhesus tumors and hamsters, Regeneron said this month.
Together with Roche, Regeneron aims to increase the overall production capacity of REGN-COV2 by at least three and a half times in a bid to meet any US and global need. Roche’s move to join forces with Regeneron comes after his own drug, Actemra, failed in a trial against Covid-19.
“REGN-COV2 could provide a highly needed treatment option for people who already have symptoms of COVID-19, and also has the potential to prevent infection in people exposed to the virus, thus slowing the spread of the global pandemic,” said Roche in a statement.
The companies will jointly fund and conduct ongoing Phase 3 prevention for Late Phase and Phase 1 healthier Phase 1 health research, as well as additional global studies to further evaluate REGN-COV2 in the treatment or prevention of Covid-19 , said Roche.
.
